Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities	[1]	$ (610)	$ 823	$ (1,320)	$ 1,196
BioNTech and Cerevel [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		$ (432)	$ 917	$ (776)	1,000
BioNTech [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Proceeds from collaborators					$ 188

[1] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of July 3, 2022, there were cumulative impairments and downward adjustments of $108 million and upward adjustments of $194 million. Impairments, downward and upward adjustments were not significant in the second quarter and first six months of 2022 and 2021.